Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 6/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.53 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | RGS4 | P49798 | 1/20 | 0.42 |
| ▸ | RGS8 | P57771 | 1/20 | 0.42 |
| ▸ | EP300 | Q09472 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3489534 | 0.91 | HCRTR1 (0.52) | HTTMAPTGAAHCRTR2HCRTR1 | |
| SCHEMBL3489510 | 0.89 | MAPT (0.51) | HTTMAPTGAAHCRTR2HCRTR1 | |
| SCHEMBL3489218 | 0.86 | HTT (0.52) | HTTMAPTGAAHCRTR2HCRTR1 | |
| SCHEMBL3488978 | 0.86 | HTT (0.46) | HTTMAPTGAAHCRTR2HCRTR1 | |
| SCHEMBL3490715 | 0.85 | HTT (0.51) | HTTMAPTGAAHCRTR2HCRTR1 | |
| SCHEMBL3489094 | 0.84 | HCRTR2 (0.53) | HTTMAPTGAAHCRTR2HCRTR1 | |
| SCHEMBL3489196 | 0.80 | CMA1 (0.51) | MAPTGAAHCRTR2HCRTR1TP53 | |
| SCHEMBL3489836 | 0.79 | MAPT (0.43) | HTTMAPTHCRTR2HCRTR1TP53 | |
| SCHEMBL3490201 | 0.78 | HCRTR1 (0.47) | HTTMAPTGAAHCRTR2HCRTR1 | |
| SCHEMBL3489133 | 0.77 | F2 (0.42) | HTTMAPTHCRTR2HCRTR1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035866-A1 | NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035866-A1 | NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | OPRD1, HTR6, HTR1D | HTT 429/4885MAPT 2158/4885GAA 4362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.